Hepion Pharmaceuticals, Inc. 8-K

What Happened

• Hepion Pharmaceuticals, Inc. (HEPA) filed an 8-K reporting that former CEO Dr. Kaouthar Lbiati, who resigned for personal reasons (disclosed March 16, 2026), entered a separation agreement dated April 13, 2026. Under the agreement the company will pay specified cash amounts and reimburse COBRA health insurance payments.

Key Details

• Separation agreement effective April 13, 2026 (the Separation Date).
• Cash payments: $225,000 plus $30,625 representing a pro‑rata portion of a potential cash bonus — total $255,625.
• Company will reimburse Dr. Lbiati’s COBRA insurance premiums for six months.
• Dr. Lbiati agreed to a general release and confidentiality obligations.
• Items reported on the 8-K: Item 1.01 (Entry into a Material Definitive Agreement) and Item 5.02 (Departure of Certain Officers).

Why It Matters

• This filing confirms the formal terms and cost to the company of the CEO transition disclosed March 16, 2026, quantifying the near-term cash impact (one-time payments plus short-term COBRA reimbursements).
• Investors can use these concrete figures when assessing near-term cash needs and governance changes; the filing also documents standard post‑employment protections (release and confidentiality).